beta-alanine has been researched along with Pulmonary Embolism in 29 studies
Pulmonary Embolism: Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Less bleeding but more acute coronary events with dabigatran, and still no antidote." | 7.81 | Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug. ( , 2015) |
| "Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)." | 7.78 | [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 6.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "Rivaroxaban is the first TSOAC to gain widespread approval for the treatment of acute deep vein thrombosis and pulmonary embolism and the long-term prevention of recurrent VTE as monotherapy." | 4.90 | The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism. ( Akwaa, F; Spyropoulos, AC, 2014) |
| " The US Food and Drug Administration recently approved 2 new oral anticoagulants, dabigatran and rivaroxaban, for stroke prevention in patients with atrial fibrillation, and is currently reviewing a drug application for a third new oral anticoagulant, apixaban." | 4.89 | Novel oral anticoagulants: a review of new agents. ( Wanat, MA, 2013) |
| "The direct thrombin inhibitor, dabigatran, and the selective factor Xa inhibitors, rivaroxaban and apixaban, are new oral anticoagulants that are approved in many countries for prevention of venous thromboembolism in patients undergoing elective hip or knee arthroplasty." | 4.89 | Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery. ( Eriksson, BI; Quinlan, DJ, 2013) |
| "Indications for use of the new anticoagulants include thromboprophylaxis after total hip and knee replacement surgery (all three), prevention of stroke and systemic embolism in non-valvular atrial fibrillation (all three), treatment of acute venous thrombosis and secondary prophylaxis after venous thrombosis (currently only rivaroxaban)." | 4.89 | New oral anticoagulants--a review. ( Atar, D; Ghanima, W; Sandset, PM, 2013) |
| " Less bleeding but more acute coronary events with dabigatran, and still no antidote." | 3.81 | Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug. ( , 2015) |
| " On admission, a computed tomography angiogram revealed acute bilateral PE, despite use of dabigatran for atrial fibrillation for approximately 5 years prior to admission." | 3.79 | Acute pulmonary emboli in a patient on long-term dabigatran therapy. ( Kujawski, SZ; Prom, R; Rafferty, JA, 2013) |
| "Cost considered: the drugs for the prevention of VTE (apixaban, dabigatran, enoxaparin, fondaparinux, other heparins, rivaroxaban and warfarin) and the complications of VTE in the short term and in 5 years (deep vein thrombosis, pulmonary embolism, bleedings and the post-thrombotic syndrome)." | 3.78 | [Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement]. ( Betegón Nicolás, L; de Salas-Cansado, M; Gómez Arrayas, I; Gómez Cerezo, JF; Rubio-Terrés, C; Suárez Fernández, C, 2012) |
| " They are at least as effective and as safe as conventional therapy (heparins and vitamin-K inhibitors) and have practical advantages, such as fixed dosing and no need for laboratory monitoring." | 2.50 | Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism. ( Bounameaux, H; Fontana, P; Goldhaber, SZ, 2014) |
| "Risk for symptomatic deep venous thrombosis, but not risk for death or nonfatal pulmonary embolism, was reduced with factor Xa inhibitors compared with LMWH (4 fewer events per 1000 patients)." | 2.49 | Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review. ( Adam, SS; Lachiewicz, PF; McDuffie, JR; Ortel, TL; Williams, JW, 2013) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 2.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "Based on these results, prevention and treatment of venous thromboembolism will change substantially in the near future." | 1.37 | [New anticoagulants in the prevention and treatment of venous thromboembolism]. ( Keltai, K; Keltai, M, 2011) |
| "Dabigatran has been granted authorisation by the FDA in non-valvular atrial fibrillation (RE-LY trial) while rivaroxaban is expecting approval in this same indication (ROCKET trial)." | 1.37 | [Pharmacologic heterogeneity of new anticoagulants]. ( Combe, S; Conard, J; Flaujac, C; Horellou, MH; Samamaa, MM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 29 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guijarro Merino, R | 1 |
| Villalobos Sánchez, A | 1 |
| Rafferty, JA | 1 |
| Prom, R | 1 |
| Kujawski, SZ | 1 |
| King, CS | 1 |
| Holley, AB | 1 |
| Moores, LK | 1 |
| El-Daly, I | 1 |
| Reidy, J | 1 |
| Culpan, P | 1 |
| Bates, P | 1 |
| Wanat, MA | 1 |
| Agnelli, G | 1 |
| Becattini, C | 1 |
| Franco, L | 1 |
| Quinlan, DJ | 1 |
| Eriksson, BI | 1 |
| Cohen, AA | 1 |
| Rider, T | 1 |
| Adam, SS | 1 |
| McDuffie, JR | 1 |
| Lachiewicz, PF | 1 |
| Ortel, TL | 1 |
| Williams, JW | 1 |
| Ghanima, W | 1 |
| Atar, D | 1 |
| Sandset, PM | 1 |
| Prandoni, P | 1 |
| Barbar, S | 1 |
| Milan, M | 1 |
| Vedovetto, V | 1 |
| Pesavento, R | 1 |
| Wood, P | 1 |
| Fontana, P | 1 |
| Goldhaber, SZ | 1 |
| Bounameaux, H | 1 |
| Chatterjee, S | 1 |
| Sardar, P | 1 |
| Giri, JS | 1 |
| Ghosh, J | 1 |
| Mukherjee, D | 1 |
| Akwaa, F | 1 |
| Spyropoulos, AC | 1 |
| Ulrich, LR | 1 |
| Mergenthal, K | 1 |
| Petersen, JJ | 1 |
| Roehl, I | 1 |
| Rauck, S | 1 |
| Kemperdick, B | 1 |
| Schulz-Rothe, S | 1 |
| Berghold, A | 1 |
| Siebenhofer, A | 1 |
| Sengupta, N | 1 |
| Feuerstein, JD | 1 |
| Patwardhan, VR | 1 |
| Tapper, EB | 1 |
| Ketwaroo, GA | 1 |
| Thaker, AM | 1 |
| Leffler, DA | 1 |
| Karetová, D | 1 |
| Bultas, J | 1 |
| Walti, C | 1 |
| Bächli, E | 1 |
| Oliver, M | 1 |
| Loke, YK | 1 |
| Kwok, CS | 1 |
| Keltai, M | 1 |
| Keltai, K | 1 |
| Galanis, T | 1 |
| Kraft, WK | 1 |
| Merli, GJ | 1 |
| Samamaa, MM | 1 |
| Conard, J | 1 |
| Flaujac, C | 1 |
| Combe, S | 2 |
| Horellou, MH | 1 |
| Büller, HR | 1 |
| Best, M | 1 |
| Palmer, K | 1 |
| Jones, QC | 1 |
| Wathen, CG | 1 |
| Gómez Arrayas, I | 1 |
| Suárez Fernández, C | 1 |
| Gómez Cerezo, JF | 1 |
| Betegón Nicolás, L | 1 |
| de Salas-Cansado, M | 1 |
| Rubio-Terrés, C | 1 |
16 reviews available for beta-alanine and Pulmonary Embolism
| Article | Year |
|---|---|
[Prophylaxis of venous thromboembolism in orthopedic surgery. Role of the new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2012 |
Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors | 2013 |
Thromboprophylaxis in patients with pelvic and acetabular fractures: A short review and recommendations.
Topics: Acetabulum; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Coumarins; Dabigatran; Fondaparin | 2013 |
Novel oral anticoagulants: a review of new agents.
Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration S | 2013 |
New oral anticoagulants for the treatment of venous thromboembolism.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Ad | 2013 |
Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement; Benzimidazoles; beta-Alanine; Dabig | 2013 |
NOACs for thromboprophylaxis in medical patients.
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administr | 2013 |
Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Kne | 2013 |
New oral anticoagulants--a review.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; | 2013 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; | 2014 |
Direct oral anticoagulants in the treatment and long-term prevention of venous thrombo-embolism.
Topics: Acute Disease; Administration, Oral; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials, P | 2014 |
Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Dabigat | 2014 |
The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Em | 2014 |
[Direct acting oral anticoagulants in venous thromboembolism].
Topics: Administration, Oral; Aged; Anticoagulants; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; | 2015 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhib | 2011 |
Prophylaxis for deep vein thrombosis and pulmonary embolism in the surgical patient.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa | 2011 |
13 other studies available for beta-alanine and Pulmonary Embolism
| Article | Year |
|---|---|
Dabigatran "non-inferior" to warfarin, but only just.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials a | 2013 |
Acute pulmonary emboli in a patient on long-term dabigatran therapy.
Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; | 2013 |
New oral anticoagulants: an emergency department overview.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Australia; Benzimidazoles; beta-Alanine; | 2013 |
Anticoagulant treatment in German family practices - screening results from a cluster randomized controlled trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; | 2014 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; E | 2015 |
[Extended options of anticoagulant treatment in thromboembolism].
Topics: Administration, Oral; Aged; Antithrombins; Benzimidazoles; beta-Alanine; Czech Republic; Dabigatran; | 2014 |
Dabigatran (Pradaxa): deep vein thrombosis and pulmonary embolism. Warfarin remains the standard drug.
Topics: Administration, Oral; Anticoagulants; Benzimidazoles; beta-Alanine; Blood Coagulation; Blood Coagula | 2015 |
Warfarin or not.
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Hemorrhage; Humans; Pulmonary Embolism; Ve | 2010 |
[New anticoagulants in the prevention and treatment of venous thromboembolism].
Topics: Administration, Oral; Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Clinical Trials a | 2011 |
[Pharmacologic heterogeneity of new anticoagulants].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; bet | 2011 |
[New treatments for venous thromboembolic disease].
Topics: Anticoagulants; Benzimidazoles; beta-Alanine; Dabigatran; Heparin; Humans; Morpholines; Pulmonary Em | 2011 |
Acute adrenal failure following anticoagulation with dabigatran after hip replacement and thrombolysis for massive pulmonary embolism.
Topics: Adrenal Gland Diseases; Adrenal Insufficiency; Aged; Antithrombins; Arthroplasty, Replacement, Hip; | 2013 |
[Budgetary impact for the National Health System of apixaban prophylaxis of venous thromboembolism in patients undergoing total knee or hip replacement].
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazole | 2012 |